Nebenwirkungen immunonkologischer Therapien

Benesova, Karolina und Leipe, Jan (2020): Nebenwirkungen immunonkologischer Therapien. In: Aktuelle Rheumatologie, Bd. 45, Nr. 06: S. 535-543

Abstract

Cancer immunotherapy with immune checkpoint inhibitors (ICPi) as the major representatives of this novel substance class are increasingly applied in a growing number of solid and haematological malignancies and stages. Remarkable tumour response rates, even in advanced and refractory stages, have revolutionised the possibilities in the field of oncology. However, the increasing use of ICPi therapies also poses unprecedented challenges: immunotherapies cause a diverse spectrum of autoimmune side-effects, known as "immune-related adverse events" (irAEs), which resemble classic autoimmune diseases and involve virtually any organ system. The majority of ICPi-treated patients are affected by an irAE in at least one organ system and approx. 5-20 % present with a rheumatic irAE. Interestingly, these are associated with better tumour response to ICPi therapy and can either be the initial manifestation of a classic rheumatic disease or only a transient side-effect with specific characteristics. Undoubtedly, the interdisciplinary management of immune-related side-effects will increasingly occupy rheumatologists in the coming years. This article summarises what practicing rheumatologists needs to know about the clinical management of irAEs.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0341-051X
• Sprache: Deutsch